Nasal polyposis treatment sales will rise through 2036, driven by pharmacological therapies at 63.5% of the type of treatment segment in 2026. The market is projected to grow from USD 5.6 billion in 2026 to USD 10.1 billion by 2036, creating an incremental opportunity of USD 4.59 billion.